Multiple Sclerosis Clinical Trial

Study of SPARC1103 in Subjects With Spasticity

Summary

Study of SPARC1103 in subjects with spasticity

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men and women greater than or equal to 18 years of age
Willing to sign the informed consent form
Women of child bearing potential willing to practice an acceptable method of birth control
Known history of spasticity due to MS

Exclusion Criteria:

Administration of an investigational drug or device within 30 days prior to Screening Visit 1
Unable to comply with trial procedures in the opinion of the Investigator
Concomitant neurologic conditions causing spasticity
Any medical condition, including psychiatric disease or epilepsy, which would interfere with the interpretation of the trial results

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

142

Study ID:

NCT02027025

Recruitment Status:

Completed

Sponsor:

Sun Pharma Advanced Research Company Limited

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

SPARC Site 4
Long Beach California, , United States
SPARC Site 6
San Diego California, , United States
SPARC Site 10
Aurora Colorado, , United States
SPARC Site 2
Jacksonville Florida, , United States
SPARC Site 7
Miami Springs Florida, , United States
SPARC Site 15
Miami Florida, , United States
SPARC Site 5
Orlando Florida, , United States
SPARC Site 13
Tampa Florida, , United States
SPARC Site 11
Kansas City Kansas, , United States
SPARC Site 3
Lenexa Kansas, , United States
SPARC Site 1
Bingham Farms Michigan, , United States
SPARC Site 14
Albuquerque New Mexico, , United States
SPARC Site 9
Charlotte North Carolina, , United States
SPARC Site 8
Cleveland Ohio, , United States
SPARC Site 12
Richland Washington, , United States
SPARC Site 18
Moscow , , Russian Federation
SPARC Site 17
Nizhniy Novgorod , , Russian Federation
SPARC Site 20
Samara , , Russian Federation
SPARC Site 19
Smolensk , , Russian Federation
SPARC Site 16
Ufa , , Russian Federation
SPARC Site 22
Dnepropetrovsk , , Ukraine
SPARC Site 21
Ivano-Frankivs'k , , Ukraine
SPARC Site 23
L'viv , , Ukraine

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

142

Study ID:

NCT02027025

Recruitment Status:

Completed

Sponsor:


Sun Pharma Advanced Research Company Limited

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider